Cristina Gasparetto
Professor of Medicine · Duke Department of Medicine
Credentials: ·
History
- Present
Duke Department of Medicine
- Present
Duke Cancer Institute
Research
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Blood · 2017 · 428 citations
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
New England Journal of Medicine · 2022 · 422 citations
The Lancet Oncology · 2020 · 342 citations
57 papers
55 papers
48 papers
43 papers
34 papers
21 papers
19 papers
19 papers
Grants
- 2002–2007
Dendritic Cell Based Vaccination for Multiple Myeloma
National Cancer Institute · K08
Contact PI · $654.9K · Duke University
Clinical trials
- 2016–2024
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
Principal investigator · Unknown · Phase 2
Cristina Gasparetto
- 2008–2014
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Principal investigator · Completed · Phase 2
Cristina Gasparetto
- 2008–2012
Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Principal investigator · Terminated · Phase 1
Duke University
- 2004–2008
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
Principal investigator · Completed · Phase 2
Duke University